Use of Ketamine Prior to Cardiopulmonary Bypass in Children

Related Clinical Trial
The Effect of Transcatheter Ventricular Septal Defect Closure on Heart Rate Variability Parameters Improving Care for Children With Congenital Heart Disease. Lifetech MFO Post-Market Clinical Follow-Up Study Evaluation of Latent Pulmonary Arterial Hypertension in Congenital Shunt Lesions A Phase I Study of Dexmedetomidine Bolus and Infusion in Corrective Infant Cardiac Surgery: Safety and Pharmacokinetics Optical Tissue Identification for Myocardial Architecture Measures to Lower the Stress Response in Pediatric Cardiac Surgery Cardiac Function After Transcatheter VSD Closure The Effect of Remote Ischemic Preconditioning on the Ischemic Reperfusion Injury in Infants With Ventricular Septal Defect and Pulmonary Hypertension A Trial to Evaluate the Safety and Efficacy of a Fully Degradable Ventricular Septal Defect (VSD) Closure Closure of Muscular Ventricular Septal Defects (VSDs) With the AMPLATZER Muscular VSD (MuVSD) Occluder – Post Approval Study The Cardiopulmonary Effect of Inhaled Beta-2-agonists on Adult Patients Born With Ventricular Septum Defects. Intravenous L-Citrulline to Treat Children Undergoing Heart Bypass Surgery : Revised Protocol Optimal Timing for Repair of Left to Right Shunt Lesions Use of Ketamine Prior to Cardiopulmonary Bypass in Children Aberrations in Carnitine Homeostasis in Congenital Heart Disease With Increased Pulmonary Blood Flow Transcatheter Closure Versus Surgery of Perimembranous Ventricular Septal Defects Cardiopulmonary Function in Adults Born With a Ventricular Septal Defect Longterm Outcome After Ventricular Septal Defect Closure Closure of Perimembranous Ventricular Septal Defects With The AMPLATZER® Membranous VSD OCCLUDER Hybrid Closure of Congenital Heart Disease

Brief Title

Use of Ketamine Prior to Cardiopulmonary Bypass in Children

Official Title

Use of Ketamine Prior to Cardiopulmonary Bypass in Children

Brief Summary

      To assess whether the drug ketamine given prior to cardiopulmonary bypass can decrease injury
      to the cells in the brain.
    


Study Phase

Phase 2

Study Type

Interventional


Primary Outcome

To compare expression of serum markers of CNS injury

Secondary Outcome

 to compare the clinical, radiological and neurodevelopmental outcomes of the cases and controls

Condition

Ventricular Septal Defect

Intervention

saline

Study Arms / Comparison Groups

 1
Description:  

Publications

* Includes publications given by the data provider as well as publications identified by National Clinical Trials Identifier (NCT ID) in Medline.

Recruitment Information


Recruitment Status

Drug

Estimated Enrollment

24

Start Date

July 2004

Completion Date

November 2007


Eligibility Criteria

        Inclusion Criteria:

          -  less than one year of age

          -  undergoing cardiac surgery for repair of ventricular septal defect

          -  requiring cardiopulmonary bypass

          -  not requiring retrogrades cerebral perfusion

        Exclusion Criteria:

          -  Downs Syndrome
      

Gender

All

Ages

N/A - 1 Year

Accepts Healthy Volunteers

No

Contacts

Adnan T Bhutta, MD, , 

Location Countries

United States

Location Countries

United States

Administrative Informations


NCT ID

NCT00556361

Organization ID

28781 Bhutta

Secondary IDs

CUMG


Study Sponsor

Arkansas Children's Hospital Research Institute


Study Sponsor

Adnan T Bhutta, MD, Principal Investigator, Arkansas Children's Hospital Research Institute


Verification Date

November 2007